Gyre Therapeutics, Inc. GYRE Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $37.5M+149% | $37.07M+214% | $40.4M+155% | $36.49M+127% | $15.05M-49.5% | ||
| $12.31M-17.1% | $15.36M+3.3% | $19.65M— | $17.87M— | $14.85M— | ||
| $104.35M+34.0% | $101.73M+39.1% | $90.25M+30.6% | $83.86M+69.2% | $77.85M+152% | ||
| $39.24M+49.6% | $35.76M+53.6% | $31.93M+50.4% | $29.46M+111% | $26.23M+221% | ||
| $3.76M-53.9% | $2.83M+7.7% | $2.87M+89.9% | $2.7M— | $8.16M— | ||
| $91.73M+34.0% | $102.37M+58.0% | $98.58M+79.9% | $91.29M+70.6% | $68.45M+9.1% | ||
| $23.57M+0.2% | $23.6M-1.2% | $23.61M-3.4% | $23.4M— | $23.52M— | ||
| $4.63M-9.0% | $4.73M+1,632% | $4.85M+2,534% | $4.96M— | $5.08M— | ||
| $7.72M+32.7% | $6.87M+22.3% | $6.71M+30.1% | $6.13M— | $5.82M— | ||
| $4.94M-11.1% | $5.05M+66.6% | $5.32M+92.4% | $5.34M+318% | $5.56M+593% | ||
| $162.02M+24.8% | $166.13M+32.5% | $159.38M+27.3% | $152.65M+26.2% | $129.79M+6.4% | ||
| $265K+117% | $124K+14.8% | $556K+83.5% | $71K-73.8% | $122K-63.0% | ||
| $226K-0.9% | $227K0.0% | $228K-82.3% | $219K-85.2% | $228K-83.3% | ||
| $840K+2,900% | $14K-77.0% | $58K-68.6% | $0— | $28K— | ||
| $751K-6.7% | $636K-10.8% | $626K-9.8% | $622K— | $805K— | ||
| $3.13M+450% | $2.94M+3.9% | $2.65M-6.9% | $1.08M— | $569K— | ||
| $19.79M+4.2% | $18.29M-6.3% | $15.91M+8.1% | $16.92M+8.6% | $18.99M-2.5% | ||
| $72K-90.8% | $303K-65.8% | $539K-51.0% | $771K— | $780K— | ||
| $823K-48.1% | $939K-41.2% | $1.17M-35.1% | $1.39M— | $1.59M— | ||
| $1.46M+4.2% | $1.45M+20,586% | $1.43M+71,250% | $1.43M— | $1.4M— | ||
| $25.03M-1.8% | $23.85M-11.7% | $21.97M-17.9% | $23.2M-15.9% | $25.49M-23.3% | ||
| $91K+4.6% | $91K+5.8% | $91K+7.1% | $91K+7.1% | $87K+2.4% | ||
| $174.65M+26.4% | $172.05M+26.3% | $167.13M+24.5% | $161.44M+20.8% | $138.18M+3.7% | ||
| -$77.67M-9.8% | -$68.43M+6.8% | -$66.7M+9.1% | -$70.31M+5.6% | -$70.76M+9.3% | ||
| $586K+124% | -$779K+70.0% | -$1.7M-79.7% | -$2.29M— | -$2.49M— | ||
| $35.68M-1.4% | $36.25M+3.3% | $35.5M+0.6% | $37.42M— | $36.18M— | ||
| $101.31M+48.7% | $106.03M+67.5% | $101.92M+61.3% | $92.03M+52.5% | $68.12M+20.3% | ||
| $162.02M+24.8% | $166.13M+32.5% | $159.38M+27.3% | $152.65M+26.2% | $129.79M+6.4% | ||
| $3.82M— | $5.64M— | $693K— | —— | —— | ||
| $4.94M-11.1% | $5.05M+66.6% | $5.32M+92.4% | $5.34M+318% | $5.56M+593% | ||
| $7.72M+32.7% | $6.87M+22.3% | $6.71M+30.1% | $6.13M— | $5.82M— | ||
| $4.63M-9.0% | $4.73M+1,632% | $4.85M+2,534% | $4.96M— | $5.08M— | ||
| $29.42M+37.7% | $23.52M-4.3% | $20.32M-31.2% | $21.53M— | $21.37M— | ||
| $4.94M-11.1% | $5.05M+66.6% | $5.32M+92.4% | $5.34M+318% | $5.56M+593% | ||
| $12.31M-17.1% | $15.36M+3.3% | $19.65M— | $17.87M— | $14.85M— | ||
| $4.94M-11.1% | $5.05M+66.6% | $5.32M+92.4% | $5.34M+318% | $5.56M+593% | ||
| $3.13M+450% | $2.94M+3.9% | $2.65M-6.9% | $1.08M— | $569K— | ||
| $226K-0.9% | $227K0.0% | $228K-82.3% | $219K— | $228K— | ||
| $2.87M-15.9% | $2.96M-47.8% | $3.22M-45.0% | $3.2M— | $3.41M— | ||
| $15.42M-10.6% | $14.36M+35.3% | $11.8M+23.5% | $14.92M— | $17.24M— | ||
| $840K-7.2% | $852K-8.2% | $866K+368% | $884K— | $905K— | ||
| $823K-48.1% | $939K-41.2% | $1.17M-35.1% | $1.39M— | $1.59M— | ||
| $91K+4.6% | $91K+5.8% | $91K+7.1% | $91K+7.1% | $87K+2.4% | ||
| $3.65M+17.8% | $3.1M0.0% | $3.1M0.0% | $3.1M— | $3.1M— | ||
| $2.87M-15.9% | $2.96M-47.8% | $3.22M-45.0% | $3.2M— | $3.41M— | ||
| $35.68M-1.4% | $36.25M+3.3% | $35.5M+0.6% | $37.42M— | $36.18M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Gyre Therapeutics, Inc.'s total assets?
- Gyre Therapeutics, Inc. (GYRE) holds $162.0M in total assets, up 24.8% year over year.
- How much debt does Gyre Therapeutics, Inc. have?
- Gyre Therapeutics, Inc. carries $823.0K in total debt against $101.3M of shareholders' equity, a debt-to-equity ratio of 0.01.
- How much cash does Gyre Therapeutics, Inc. have?
- Gyre Therapeutics, Inc. holds $37.5M in cash and equivalents.
- Can Gyre Therapeutics, Inc. cover its short-term obligations?
- Its current ratio is 4.64 — current assets exceed current liabilities.
- Where does Gyre Therapeutics, Inc.'s balance sheet data come from?
- Every line is extracted from Gyre Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
